Login
← Go Back
Supriya Lifescience
SUPRIYA · Pharma > Pharmaceuticals & Drugs · Chairman: Satish Waman Wagh · MD: Satish Waman Wagh · Listing date: Dec. 29, 2021
Stock Price vs Company Growth
1d
3.1%
1w
5.0%
1m
22.5%
3m
9.5%
6m
30.0%
1y
101.5%
all
14.1%
Created with Highcharts 8.2.2SalesProfitPriceDividendQtr SalesOperating CashflowMar21Dec21Sep22Jun23Mar24Latest
🤔 How to analyze this graph?
Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price
₹ 733 3.1%
557
842
Company Overview
Sales
671 Cr
Growth: 16.3%
Profit after Tax
175 Cr
Growth: 10.8%
Small Cap
5,899 Cr
P/E: 33.8x
Industry P/E: 29.6x
Created with Highcharts 8.2.2HistoricalGrowthValuationAttractivenessProfitabilityIndustryOutlookPriceStability10
Fundamentals
Sales (Cr) ₹ 671
Growth 16.3%
EBITDA 37.1%
P/S 8.8x
Dividend 0.1%
P/E 33.8x
Book Value ₹ 2
PEG Ratio 2.1x
ROE 999.0%
P/B N/A
Shareholding Pattern
Institutions
Created with Highcharts 8.2.2Mar22Dec22
Promoters
Created with Highcharts 8.2.2Mar22Dec22
Others
Created with Highcharts 8.2.2Mar22Dec22
Increase    Decrease    No change
Company Profile Detailed
The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development. The company has niche product offerings of various APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic.
Belongs to (10 Indices) view more
Investors (6)
jyotsana
rajeev4
shivani....
Followers (1)
varsha96